dc.contributor.author |
Valenzuela, Omar |
|
dc.contributor.author |
Ibáñez, Sebastián |
|
dc.contributor.author |
Poli, Cecilia |
|
dc.contributor.author |
Roessler, Patricia |
|
dc.contributor.author |
Aylwin, Mabel |
|
dc.contributor.author |
Roizen, Gigia |
|
dc.contributor.author |
Iruretagoyena, Mirentxu |
|
dc.contributor.author |
Agar, Vivianne |
|
dc.contributor.author |
Donoso, Javiera |
|
dc.contributor.author |
Fierro, Margarita |
|
dc.contributor.author |
Montes, José Miguel |
|
dc.date.accessioned |
2022-03-28T18:37:06Z |
|
dc.date.available |
2022-03-28T18:37:06Z |
|
dc.date.issued |
2020 |
|
dc.identifier.citation |
Valenzuela O, Ibáñez S, Poli MC, Roessler P, Aylwin M, Roizen G, Iruretagoyena M, Agar V, Donoso J, Fierro M, Montes J. First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia. Front Med (Lausanne). 2020 Nov 16;7:596916. doi: 10.3389/fmed.2020.596916. |
es |
dc.identifier.uri |
https://doi.org/10.3389/fmed.2020.596916 |
es |
dc.identifier.uri |
http://hdl.handle.net/11447/5829 |
|
dc.description.abstract |
Introduction/objectives: An interleukin-6 inhibition strategy could be effective in
selected COVID-19 patients. The objective is to present our experience of tocilizumab
use in patients with severe COVID-19.
Methods: Observational retrospective cohort study. Hospitalized patients were
evaluated by our multidisciplinary team for eventual use of tocilizumab. Patients with
progressive ventilatory impairment and evidence of a hyperinflammatory state despite
usual treatment received tocilizumab 8 mg/kg intravenous (maximum dose 800 mg),
in addition to standard treatment. The use and time of use of mechanical ventilation
(MV), the change of the Alveolar-arterial (A-a) gradient, of the ratio of arterial oxygen
partial pressure to fractional inspired oxygen (PaO2/FiO2) and of inflammation laboratory
parameters after 72 h of tocilizumab use was evaluated.
Results: 29 patients received tocilizumab. 93.1% were men, 37.9% were obese, and
34.5% had hypertension. Of the 20 patients who were not on MV when receiving
tocilizumab, 11 required non-invasive MV, for an average of 5 days, and one of them
required intubation. A-a gradient, PaO2/FiO2, and inflammation parameters improved
significantly. A better lymphocyte count, which improved significantly after tocilizumab
use, was significantly associated with less use of MV. Five patients presented positive
culture samples after tocilizumab, three being of clinical significance. A lower lymphocyte
count was associated with having a positive culture. No other significant adverse events
were seen.
Conclusion: Our study suggests the utility and shows the safety of tocilizumab use
in COVID-19 patients who have respiratory failure and evidence of hyperinflammation.
Lymphocyte improvement was a predictor of good response. |
es |
dc.language.iso |
en |
es |
dc.subject |
Tocilizumab |
es |
dc.subject |
Covid-19 |
es |
dc.subject |
SARS-CoV 2 |
es |
dc.subject |
Lymphocyte |
es |
dc.subject |
Mechanical ventilalion |
es |
dc.title |
First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia |
es |
dc.type |
Article |
es |
dc.description.version |
Versión Publicada |
es |
dcterms.source |
Frontiers in Medicine |
es |